EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy

Hirotaka Kawakami, Nobuhiro Ijichi, Yuki Obama, Eriko Matsuda, Kaoru Mitsui, Yuya Nishikawaji, Maki Watanabe, Satoshi Nagano, Noboru Taniguchi, Setsuro Komiya, Ken-Ichiro Kosai

Translational Research · 2024

DOI: 10.1016/j.trsl.2024.07.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024. Verfasst von Hirotaka Kawakami und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagosh…. Hauptthemen laut MEDLINE: Promoter Regions, Genetic, Transgenes, Oncolytic Virotherapy, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In general, ensuring safety is the top priority of a new modality. Although oncolytic virus armed with an immune stimulatory transgene (OVI) showed some promise, the strategic concept of simultaneously achieving maximum effectiveness and minimizing side effects has not been fully explored. We generated a variety of survivin-responsive "conditionally replicating adenoviruses that can target and treat cancer cells with multiple factors (m-CRAs)" (Surv.m-CRAs) armed with the granulocyte-macrophage colony-stimulating factor (GM-CSF) transgene downstream of various promoters using our m-CRA platform technology. We carefully analyzed both therapeutic and adverse effects of them in the in vivo syngeneic Syrian hamster cancer models. Surprisingly, an intratumor injection of a conventional OVI, which expresses the GM-CSF gene under the constitutively and strongly active "cytomegalovirus enhancer and β-actin promoter", provoked systemic and lethal GM-CSF circulation and shortened overall survival (OS). In contrast, a new conceptual type of OVI, which expressed GM-CSF under the cancer-predominant and mildly active E2F promoter or the moderately active "Rous sarcoma virus long terminal repeat", not only abolished lethal adverse events but also prolonged OS and systemic anti-cancer immunity. Our study revealed a novel concept that optimal expression levels of an immune stimulatory transgene regulated by a suitable upstream promoter is crucial for achieving high safety and maximal therapeutic effects simultaneously in OVI therapy. These results pave the way for successful development of the next-generation OVI and alert researchers about possible problems with ongoing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Promoter Regions, GeneticTransgenesOncolytic VirotherapyImmunotherapyOncolytic VirusesGranulocyte-Macrophage Colony-Stimulating FactorAnimalsCytokinesHumansCell Line, TumorCricetinaeMesocricetus

Stichwörter der Autor:innen

Cancer immunotherapyConditionally replicating adenovirus targeting and/or treating tumors with mult…Conditionally-replicating adenovirus (CRA)CytokineE2FGranulocyte macrophage colony-stimulating factor (GM-CSF)Oncolytic virusPromoter activitySafetySurvivin

Substanzen

Granulocyte-Macrophage Colony-Stimulating FactorCytokines

Autor:innen und Institutionen

  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Department of Orthopaedic Surgery, Kagoshima Univ…
  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
  • Center for Innovative Therapy Research and Application, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
  • Department of Orthopaedic Surgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Application, Kagoshima University Graduate School of Medical and Dental…
  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Applic…

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Kawakami, H., Ijichi, N., Obama, Y., Matsuda, E., Mitsui, K., Nishikawaji, Y., Watanabe, M., Nagano, S., Taniguchi, N., Komiya, S., & Kosai, K. I. (2024). An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy. Translational Research. https://doi.org/10.1016/j.trsl.2024.07.002

Vancouver

Kawakami H, Ijichi N, Obama Y, Matsuda E, Mitsui K, Nishikawaji Y, et al. An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy. Translational Research. 2024. doi:10.1016/j.trsl.2024.07.002

BibTeX
@article{Kawakami2024,
  author = {Kawakami, Hirotaka and Ijichi, Nobuhiro and Obama, Yuki and Matsuda, Eriko and Mitsui, Kaoru and Nishikawaji, Yuya and Watanabe, Maki and Nagano, Satoshi and Taniguchi, Noboru and Komiya, Setsuro and Kosai, Ken-Ichiro},
  title = {An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy},
  journal = {Translational Research},
  year = {2024},
  doi = {10.1016/j.trsl.2024.07.002}
}
Kostenlos starten →